Monday, June 6, 2016

UPDATE 1-Alexion shares slump as drug misses goal in late-stage trial

June 6 (Reuters) - Alexion Pharmaceuticals Inc said

its drug Soliris, already approved in the United States for the

treatment of two rare blood disorders, missed its primary goal

in a late-stage...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)